The aim of this review is to provide an overview of folate receptor alpha (FRα) expression in ovarian cancer, with a particular focus on its immunohistochemical evaluation using the Ventana FOLR1 RxDx Assay. Here, FOLR1 is linked to ovarian carcinoma.